Delivery Order SPE2DB22D1202-SPE2DB25FVFK9
- Not listed
- The Defense Logistics Agency awarded a $1,317.48 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 24, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,534.20 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value pharmaceutical procurement supporting military and federal...
- The Defense Logistics Agency awarded a $6,703.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside contract represents a single delivery order for pharmaceutical supplies to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the AmerisourceBergen Corporation. The $3,562.80 contract is for the provision of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This delivery order is placed under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with DLA, which has a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, valued at $1,022.80 with firm fixed pricing. This non-set-aside delivery order was awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The product is a prescription insulin delivery system used for diabetes management within the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The contract has a potential value of $1,911.67 and a completion date of March 5, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of up to $999,999,999.00 and a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $1,943.76 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin in 3ml quantities. This firm fixed price, competitively awarded contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single transaction executed...
- The Defense Logistics Agency awarded a $1,917.75 firm fixed price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin, with an ultimate completion date of July 29, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,781.40 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Lantus SoloStar insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for AmerisourceBergen to deliver...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFK9Delivery Order
The Defense Logistics Agency awarded a $3,049.07 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This firm fixed price contract, with an ultimate completion date of July 24, 2025, represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was competitively awarded with no set-aside designation, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime indefinite delivery vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs globally, including services to the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal pharmaceutical contracts demonstrates its established capability to fulfill critical medical supply requirements for the Department of Defense medical supply chain on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 7/23/25 |